Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy

2000 ◽  
Vol 108 (03) ◽  
pp. 168-174 ◽  
Author(s):  
E. Haak ◽  
K. Usadel ◽  
K. Kusterer ◽  
P. Amini ◽  
R. Frommeyer ◽  
...  
Keyword(s):  
Diabetic Neuropathy ◽  
Lipoic Acid ◽  
Alpha Lipoic Acid ◽  
Peripheral Diabetic Neuropathy

Alpha-lipoic acid and coenzyme Q10 combination ameliorates experimental diabetic neuropathy by modulating oxidative stress and apoptosis

Life Sciences ◽  
2019 ◽  
Vol 216 ◽  
pp. 101-110 ◽  
Author(s):  
Nasrin Sadeghiyan Galeshkalami ◽  
Mohammad Abdollahi ◽  
Rezvan Najafi ◽  
Maryam Baeeri ◽  
Akram Jamshidzade ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Diabetic Neuropathy ◽  
Lipoic Acid ◽  
Coenzyme Q10 ◽  
Alpha Lipoic Acid ◽  
Experimental Diabetic Neuropathy

scholarly journals Evaluating the Efficacy of the Treatment with Benfotiamine and Alpha-lipoic Acid in Distal Symmetric Painful Diabetic Polyneuropathy

2019 ◽  
Vol 70 (9) ◽  
pp. 3108-3114 ◽  
Author(s):  
Amorin Remus Popa ◽  
Simona Bungau ◽  
Cosmin Mihai Vesa ◽  
Andrei Cristian Bondar ◽  
Carmen Pantis ◽  
...  
Keyword(s):  
Diabetic Neuropathy ◽  
Lipoic Acid ◽  
Combined Therapy ◽  
Visual Analogue Pain Scale ◽  
Alpha Lipoic Acid ◽  
Painful Diabetic Neuropathy ◽  
Disability Score ◽  
Visual Analogue Pain ◽  
Hexosamine Pathway ◽  
Lower Limb Pain

Distal symmetric painful diabetic neuropathy is the most frequent clinical form of diabetic neuropathy. The condition appears as a result of alteration of the structure and function of nervous fibres as a consequence of hyperglycaemia. Hyperglycaemia determines the metabolism of glucose on alterative pathways and generates increased oxidative stress, mechanisms that cause an accelerated apoptosis of the neurons and a high intensity of lipid peroxidation. Pathogenic treatment of diabetic neuropathy includes limited options, two of them are: Benfotiamine (inhibits the metabolism of glucose on hexosamine pathway, reducing the formation of advanced glycosylation end products) and alpha-lipoic acid (has a scavenger effect on free radical species). The study included 120 patients with distal symmetric painful diabetic neuropathy randomized in 3 treatment groups. We evaluated the effect of oral administration for 8 weeks of Benfotiamine in a dosage of 300mg/day in monotherapy, of alpha-lipoic acid in a dosage of 600 mg/day in monotherapy, respectively of both -in combined therapy - on the parameters that are used to determine the severity of distal symmetric painful diabetic neuropathy: Diabetic Neuropathy Symptoms score, Neuropathy Disability Score and the intensity of lower limb pain on the visual analogue pain scale. All the three therapies were effective with a statistically significant improvement of these parameters, but the combined therapy with alpha-lipoic acid and Benfotiamine was superior to the monotherapy with alpha-lipoic acid or Benfotiamine.

scholarly journals Alpha-Lipoic Acid and Diabetic Neuropathy

2009 ◽  
Vol 6 (4) ◽  
pp. 230-236 ◽  
Author(s):  
Natalia Vallianou ◽  
Angelos Evangelopoulos ◽  
Pavlos Koutalas
Keyword(s):  
Diabetic Neuropathy ◽  
Lipoic Acid ◽  
Alpha Lipoic Acid

scholarly journals The effects of the physical procedures in patients with diabetic neuropathy

2019 ◽  
Vol 76 (8) ◽  
pp. 787-794
Author(s):  
Vesna Grbovic ◽  
Srdjan Stefanovic ◽  
Svetlana Djukic ◽  
Jasmin Nurkovic ◽  
Natasa Zdravkovic-Petrovic ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Physical Therapy ◽  
Diabetic Neuropathy ◽  
Lipoic Acid ◽  
Pain Reduction ◽  
Life Questionnaire ◽  
Alpha Lipoic Acid ◽  
Group A ◽  
Group B

Background/Aim. Neuropathy represents the most frequent complication in the patients with diabetes mellitus (DM). Symmetric distal sensorimotor polyneuropathy (DSP), which represents the most frequent type of diabetic neuropathy, is present in 30% of hospitalized diabetic patients. The aim of our study was to compare the effects of physical therapy (PT) and alpha-lipoic acid (ALA) supplementation on pain reduction and quality of life improvement in the DSP patients. Methods. The study was performed on 60 adult patients with DM type 2 and DSP. The patients were randomly divided into 2 groups: group A (n = 30) was treated by PT and group B (n = 30) was treated by ALA. The study lasted 6 months during which 3 diagnostictherapeutic cycles were performed. To asses their pain before and after every of 3 cycles, we used visual analog scale (VAS). We also evaluated quality of life before the 1st and after the 3rd cycle with the European Quality of Life Questionnaire (EQ-5D-3L). To analyze results between groups we used mixed between-within subjects ANOVA and statistical significance was set on p < 0.05. Results. Pain intensity showed statistically significant influence of both PT and ALA (? = 0.028; p < 0.001). A statistically significant difference between the effects of those two therapy modalities was observed (F = 4.78; p < 0.05): PT reduced pain to the greater extent than ALA. A statistically significant improvement was found in the domain of pain/discomfort both in the group A (? = 0.54, p < 0.001) and group B (? = 0.57, p < 0.001), as well as anxiety/depression (group A: ? = 0.32, p = 0.008; group B: ? = 0.22, p < 0.019) and EQ-VAS (both groups, p < 0.05). Conclusion. Our research showed that physical therapy had a greater influence in pain reduction than alpha-lipoic acid in the patients with DSP.

Studying the Effect of Adding Alpha Lipoic Acid to Gabapentin to Improve Nerve Conduction Velocity and Glycemic Control of Patients with Diabetic Neuropathy (Sample of Iraqi population)

2020 ◽  
pp. 55-62
Keyword(s):  
Glycemic Control ◽  
Diabetic Neuropathy ◽  
Conduction Velocity ◽  
Lipoic Acid ◽  
Nerve Conduction ◽  
Nerve Conduction Velocity ◽  
Clinical Symptoms ◽  
Alpha Lipoic Acid ◽  
Once Daily ◽  
Significant Change

Diabetic neuropathy (DN) is the most common chronic complication of diabetes mellitus. Hyperglycemia-induced oxidative stress induces programmed cell death of nerves, which contributes to the pathology of Diabetic neuropathy. Many clinical trials depend on supplement, in an attempt to improve neuropathy symptoms such as (pain & tingling) and patient quality of life, one of them is alpha-lipoic acid (ALA). Alpha-lipoic acid is a potent anti-inflammatory and antioxidant with insulin-mimetic activity, it has been shown to improve clinical symptoms in experimental Diabetic neuropathy and protect peripheral nerves from ischemia, in addition to stimulate the nerve growth factor and promote fiber regeneration. This study is aimed to evaluate the effect of Alpha-lipoic acid supplement as adjuvant therapy to gabapentin in patients with diabetic neuropathy, which can reflect by the improvement in nerve conduction velocity (NCV) a test was conducted to assess the severity of iabetic neuropathy and clinical symptoms. A prospective randomized- open-label interventional study for 3 months include 33 DN patients, aged (18-69) years were divided into two groups; group A include 16 patients received gabapentin 300 mg once daily at night, and group B include 17 patients received gabapentin 300 mg once daily at night plus alpha-lipoic acid 600mg once daily. Pre and post 3 months of treatment, blood samples used to measure metabolic biomarkers (FBG, HbA1c), in addition to Nerve conduction velocity. The results showed that, the intervention group produced a highly significant change in HbA1c & no significant change in FBG levels after 3months of Alpha-lipoic acid supplementation. Meanwhile, there is no significant change in HbA1c & FBG levels in patients treated with gabapentin alone. Moreover, results showed highly significant improvement (P˂0.01) in Nerve conduction velocity for two groups at the end of the study. Addition of Alpha-lipoic acid to gabapentin in diabetic neuropathy patients result to improve the glycemic control & Nerve conduction velocity. after three months of treatment.

Alpha-lipoic acid

2006 ◽  
Vol 238 ◽  
pp. 1-2
Keyword(s):  
Diabetic Neuropathy ◽  
Lipoic Acid ◽  
Toxic Metals ◽  
Animal Studies ◽  
Clinical Evidence ◽  
Alpha Lipoic Acid ◽  
Clinical Indications

In a nutshellALA is a powerful antioxidant, both water and lipid soluble, that can also regenerate other antioxidants.A range of ‘antioxidant’ and other clinical indications (such as chelating toxic metals) have been tested in small, open trials and/or animal studies. The most convincing clinical evidence so far is for a possible role in diabetes, particularly in treating diabetic neuropathy.

Sign in / Sign up

Export Citation Format

Share Document